Is eXoZymes, Inc. (EXOZ) overvalued? · rev $70.1K
eXoZymes, Inc. (EXOZ) is a biotechnology company listed on US.
This page asks whether eXoZymes, Inc. (EXOZ) looks expensive on cached numbers — not a short thesis.
Latest reported EXOZ revenue for 2023-12-31 was $70.1K. Net income was -$2.0M. Revenue was down 1.0% from 2023-09-30 to 2023-12-31. EXOZ currently screens at market cap $83.5M.
EXOZ currently screens at market cap $83.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EXOZ 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EXOZ stock page for the full model, not this heading.
Not investment advice.